A New PARP Drug For Breast Cancer? I’m Thrilled!
Another day, another breast cancer drug with a long name and limited benefit. Or at least that’s how it might seem. Yet I am thrilled. This month in San Antonio, Dr. Jennifer Litton presented initial findings from a randomized, open-label study of an experimental PARP inhibitor (talazoparib, Pfizer) in metastatic breast cancer.
